Change in number of shares and votes in EQL Pharma AB

During September 2025, the number of shares and votes in EQL Pharma AB (“EQL Pharma”) has increased as a result of the exercise of warrants issued pursuant to two warrant programs adopted by the annual general meeting on 17 August 2021 and the extraordinary general meeting on 10 December 2021, respectively.

As of 30 September 2025, the total number of shares and votes in EQL Pharma amounts to 29,529,610.

This disclosure contains information that EQL Pharma is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person, on 30-09-2025 10:00 CET.

For more information contact:

Axel Schörling,

CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Web: www.eqlpharma.com

EQL Pharma AB (publ) in short

EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has 46 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2025 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, mainly in the Nordics and European markets. EQL Pharma AB has its operations in Lund and is listed on Nasdaq Stockholm stock market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.